Search results for "GiST"

showing 10 items of 3463 documents

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct

Short term prognostic role of NT-proBNP in patients after myocardial infarction

2009

Aim. The clinical and prognostic role of cardiac natriuretic peptides (CNP) in patients with heart failure is well known; recently, several studies have evaluated the possibility of using CNP to evaluate their potential prognostic role in patients with acute coronary syndromes (ACS). The aim of this study was to evaluate the short term prognostic value of NT-proBNP in 70 patients admitted for ACS. Methods. The authors studied 70 patients with ACS, evaluating, at admission, clinical-anamnestic, instrumental and laboratory characteristics including NT-proBNP plasma levels. Patients were monitored in a 6-month-follow-up to record adverse fatal events and their possible correlation with baselin…

MaleTime FactorsMyocardial InfarctionMiddle AgedPrognosisSettore MED/11 - Malattie Dell'Apparato CardiovascolareNT-proBNP myocardial infarctionPeptide FragmentsLogistic ModelsPredictive Value of TestsRisk FactorsNT-proBNPNatriuretic Peptide BrainHumansFemaleBiomarkersAgedFollow-Up StudiesRetrospective Studies
researchProduct

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

2020

Objective Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI >= 75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI >= 75 years. Methods We included 979 patients with STEMI >= 75 years, from the ATencion HOspitalaria del Sindrome coronario study, a registry of 8142 consecutive patients with acute coronary syndrome admitted at 31 Spanish hospitals in 2014-2016. We calculated a propensity score (PS) for the indication of P-P…

MaleTime FactorsPercutaneoussistema de registrosmedicine.medical_treatmenthumanosComorbidityCoronary Artery Disease030204 cardiovascular system & hematologyLogistic regression0302 clinical medicineRecurrenceRisk Factorsevaluación de riesgosST segmentRegistries1506030212 general & internal medicineMyocardial infarctionAged 80 and overancianocoronary intervention (PCI)resultado del tratamientoCardiogenic shockAge FactorsShockstemiTreatment Outcomesurgical procedures operativeCardiologyFemaleAcute coronary syndromeCardiology and Cardiovascular MedicineStemiAcute coronary syndromemedicine.medical_specialtyShock CardiogenicPulmonary EdemaRisk Assessmentacute coronary syndromeedema pulmonar03 medical and health sciencesfactores de tiempoPercutaneous Coronary Interventionchoquecirugía coronaria percutáneaInternal medicinemedicinefactores de riesgoHumanscardiovascular diseasesAgedCoronary intervention (PCI)business.industryPercutaneous coronary interventionmedicine.diseaseSpainPropensity score matchingST Elevation Myocardial InfarctionbusinessrecurrenciaOpen Heart
researchProduct

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available s…

2015

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16 Wasat Mansoor,17 Kjell &amp;Ouml;berg3 1Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 2Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; 3Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden; 4Department of Medical Oncology, Ed…

MaleTime FactorsPharmaceutical ScienceOctreotideKaplan-Meier EstimateNeuroendocrine tumorsDigestive System NeoplasmsOctreotideGastroenterologychemistry.chemical_compoundDrug DiscoveryOdds RatioOriginal ResearchAged 80 and oversomatostatin analoguesDrug SubstitutionHazard ratioMiddle AgedTumor BurdenTreatment OutcomeFemalemedicine.symptomSomatostatinCarcinoid syndromemedicine.drugAdultmedicine.medical_specialtyNauseaCarcinoid tumorscarcinoid syndromeAntineoplastic AgentsCarcinoid TumorDisease-Free SurvivalDouble-Blind MethodInternal medicinemedicineHumansProgression-free survivalAgedProportional Hazards ModelsPharmacologypasireotideCancer och onkologiDrug Design Development and Therapybusiness.industrylcsh:RM1-950medicine.diseasesymptom controlPasireotidelcsh:Therapeutics. PharmacologyEndocrinologyLogistic ModelschemistryDrug Resistance NeoplasmDelayed-Action PreparationsCancer and Oncologyneuroendocrine tumorsbusinessprogression-free survival
researchProduct

Ipsilateral corticomotor responses are confined to the homologous muscle following cross-education of muscular strength

2017

Cross-education of strength occurs when strength-training 1 limb increases the strength of the untrained limb and is restricted to the untrained homologous muscle. Cortical circuits located ipsilateral to the trained limb might be involved. We used transcranial magnetic stimulation (TMS) to determine the corticomotor responses from the untrained homologous (biceps brachii) and nonhomologous (flexor carpi radialis) muscle following strength-training of the right elbow flexors. Motor evoked potentials were recorded from the untrained left biceps brachii and flexor carpi radialis during a submaximal contraction from 20 individuals (10 women, 10 men; aged 18–35 years; training group, n = 10; c…

MaleTime FactorsPhysiologyEndocrinology Diabetes and MetabolismCross-activationPhysical strengthRandom Allocation0302 clinical medicineCross activationMedicineInhibitionMotor NeuronsNutrition and DieteticsMotor CortexGeneral MedicineAnatomymusculoskeletal systemTranscranial Magnetic StimulationestotTreatment OutcomeFemalelihaskuntoMuscle ContractionAdultAgonistmedicine.medical_specialtyAdolescentmedicine.drug_classAgonistCross educationYoung Adult03 medical and health sciencesPhysical medicine and rehabilitationPhysiology (medical)Homologous chromosomeHumansMuscle StrengthMuscle SkeletalSynergistCortical circuitsExcitabilityElectromyographybusiness.industryNeural InhibitionResistance Training030229 sport sciencesEvoked Potentials MotorC600raajatbody regionsbusiness030217 neurology & neurosurgerylihasvoimaApplied Physiology, Nutrition, and Metabolism
researchProduct

Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation

2018

Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains controversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to assigned strategies. ........................................................................................................................................................... Methods and results Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data were reported. Among rate control strategies, beta-blockers …

MaleTime FactorsRate controlAction PotentialsPilot Projects030204 cardiovascular system & hematologyAmiodaroneAction Potentials/drug effectsHeart Conduction System/drug effectsCardiologists0302 clinical medicineHeart RateRisk FactorsCause of DeathAtrial Fibrillation030212 general & internal medicineRegistriesPractice Patterns Physicians'Cause of deathAged 80 and overAll-cause death; Atrial fibrillation; Major adverse events; Rate control; Registry; Rhythm controlHeart Rate/drug effectsAtrial fibrillationMiddle AgedEuropeTreatment OutcomeCohortCardiologyHealthcare Disparities/trendsRhythm controlFemaleCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsCardiologists/trendsmedicine.drugmedicine.medical_specialtyMajor adverse eventsRegistryAll-cause deathAnti-Arrhythmia Agents/adverse effectsEurope/epidemiology03 medical and health sciencesHeart Conduction SystemPhysiology (medical)Internal medicineHeart ratemedicineAtrial Fibrillation/diagnosisHumansHealthcare DisparitiesAdverse effectAgedbusiness.industryProportional hazards modelmedicine.diseaseAtrial fibrillationPractice Patterns Physicians'/trendsAtrial fibrillation • Rate control • Rhythm control • Major adverse events • All-cause death • RegistryPropensity score matchingbusiness
researchProduct

Collected Transatlantic Experience From the PERICLES Registry: Use of Chimney Grafts to Treat Post-EVAR Type Ia Endoleaks Shows Good Midterm Results

2018

Purpose: The aim of this retrospective analysis was to evaluate the performance of the chimney (ch) technique in the treatment of type Ia endoleaks after standard endovascular aneurysm repair (EVAR). Methods: Between January 2008 and December 2014, 517 chEVAR procedures were performed in 13 US and European vascular centers (PERICLES registry). Thirty-nine patients (mean age 76.9±7.1 years; 33 men) were treated for persistent type Ia endoleak and had computed tomography angiography or magnetic resonance angiography follow-up at &gt;1 month. Endurant abdominal stent-grafts were used in the 20 cases. Single chimney graft placement was performed in 18 (46%) patients and multiple in 21 (54%). O…

MaleTime Factorsabdominal aortic aneurysm; chimney graft; chimney technique; endoleak; endovascular aneurysm repair; juxtarenal aortic aneurysm; parallel graft; pararenal aortic aneurysm; periscope graft; snorkel graftmedicine.medical_treatmentJuxtarenal aortic aneurysm030204 cardiovascular system & hematologySettore MED/22 - Chirurgia VascolareEndovascular aneurysm repairendovascular aneurysm repair0302 clinical medicineRisk FactorsRetrospective analysisChimneyRegistries030212 general & internal medicineAged 80 and overEndovascular ProceduresChimney graftAbdominal aortic aneurysmEuropeTreatment Outcomesnorkel graftFemaleStentsjuxtarenal aortic aneurysmCardiology and Cardiovascular MedicineReoperationmedicine.medical_specialtyparallel graftendoleakperiscope graftProsthesis Designpararenal aortic aneurysmBlood Vessel Prosthesis Implantation03 medical and health sciencesabdominal aortic aneurysmchimney techniquemedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective Studiesbusiness.industrychimney graftmedicine.diseaseUnited StatesBlood Vessel ProsthesisSurgerySurgerybusinessAortic Aneurysm AbdominalJournal of Endovascular Therapy
researchProduct

Bone mineral density of the proximal femur after hip resurfacing arthroplasty: 1-year follow-up study

2011

Abstract Background Hip resurfacing arthroplasty (HRA) is considered a bone-preserving procedure and may eliminate proximal femoral stress shielding and osteolysis. However, in addition to implant-related stress-shielding factors, various patient-related factors may also have an effect on bone mineral density (BMD) of the proximal femur in patients with HRA. Thus, we studied the effects of stem-neck angle, demographic variables, and physical functioning on the BMD of the proximal femur in a one-year follow-up. Methods Thirty three patients (9 females and 24 males) with a mean (SD) age of 55 (9) years were included in the study. BMD was measured two days and 3, 6, and 12 months postoperative…

MaleTime Factorslcsh:Diseases of the musculoskeletal systemBone densityArthroplasty Replacement Hipmedicine.medical_treatmentdual energy X-ray absorptiometry02 engineering and technologySeverity of Illness IndexOsteoarthritis HipAbsorptiometry Photon0302 clinical medicineBone DensityOrthopedics and Sports MedicineFemurProspective StudiesFinlandstress shielding2. Zero hungerBone mineral030222 orthopedicsmedicine.diagnostic_teststem-neck angleMiddle AgedStress shieldingHip resurfacingREPLACEMENTTreatment Outcomemedicine.anatomical_structureFemaleResearch Articlebone remodeling dual energy X-ray absorptiometrymusculoskeletal diseasesmedicine.medical_specialtyeducation0206 medical engineering03 medical and health sciencesFemoral headPOSTERIOR APPROACHRheumatologymedicineHumansFemurPRESERVATIONbone remodelingNECKDual-energy X-ray absorptiometrybusiness.industry3126 Surgery anesthesiology intensive care radiology020601 biomedical engineeringArthroplastySurgeryLogistic Models5-YEARMODESABSORPTIOMETRYFEMORAL-HEADlcsh:RC925-935businessNuclear medicineFollow-Up StudiesBMC Musculoskeletal Disorders
researchProduct

Survival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronar…

2019

Background: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (PCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 an…

MaleTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicinetemporal trendsRisk Factorstreatment strategyST segmentMyocardial infarctionHospital MortalityRegistriesPractice Patterns Physicians'Mortality rateGeneral MedicineMiddle AgedInterventional Cardiologysurgical procedures operativeTreatment OutcomePractice Guidelines as TopicCardiologyFemaleStentsGuideline AdherenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyRisk Assessment03 medical and health sciencesPharmacotherapyPercutaneous Coronary InterventionSex FactorsInternal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeHealthcare DisparitiesAgedRetrospective Studiesbusiness.industryPercutaneous coronary interventionCardiovascular AgentsHealth Status Disparitiesmedicine.diseaseST-segment elevation myocardial infarctionConcomitantPropensity score matchingConventional PCI1-year mortalityST Elevation Myocardial InfarctionPolandbusinesssex-differencesin-hospital mortality
researchProduct